Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat.
The effects of meloxicam, piroxicam, diclofenac and tenidap on the swelling of hind paws, radiologically-detectable bone and cartilage destruction of hind paws, increase in spleen weight, increase in erythrocyte sedimentation rate and changes in serum protein composition in male Lewis rats with adjuvant arthritis were studied following once-daily oral administration of these drugs for 21 days. All the drugs dose-dependently inhibited hind paw swelling. For equal activity against hind paw swelling caused by the secondary reaction, the required daily dose of piroxicam was about twice that of meloxicam; those of diclofenac and tenidap were about 3.5 and 60 times higher respectively. The bone and cartilage destruction induced by adjuvant arthritis were inhibited by meloxicam at low daily doses and by piroxicam at doses approximately four times those of meloxicam. Diclofenac and tenidap had only a weak effect on radiologically-detectable lesions when administered at doses sufficient to reduce paw swelling. Meloxicam also had a dose-dependent corrective effect on the systemic changes which occur in adjuvant arthritic rats, e.g. increase in spleen weight, increase in erythrocyte sedimentation rate and changes in serum protein composition. Piroxicam produced similar effects, at 3-4 times higher doses. Diclofenac and tenidap did not show comparable effects when administered at appropriate doses. These findings indicate that the action of meloxicam and piroxicam differs from that of diclofenac and tenidap in adjuvant arthritis in the Lewis rat. At oral doses which significantly reduce edema formation, only meloxicam and piroxicam showed a significant effect on systemic parameters of adjuvant disease in the Lewis rat.
Engelhardt
G
G
Department of Pharmacological Research, Dr. Karl Thomae GmbH, Biberach/Riss, Germany.
Homma
D
D
Schnitzler
C
C
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D001798:Blood Proteins / Q000378:metabolism; D001799:Blood Sedimentation; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002358:Cartilage, Articular / Q000000981:diagnostic imaging / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005528:Foot / Q000000981:diagnostic imaging / Q000473:pathology; D006614:Hindlimb / Q000000981:diagnostic imaging / Q000473:pathology; D007596:Joints / Q000473:pathology; D008297:Male; D000077239:Meloxicam; D011859:Radiography; D051381:Rats; D011917:Rats, Inbred Lew; D013154:Spleen / Q000473:pathology; D013843:Thiazines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001798:Blood Proteins; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam